MIR129-1

Summary

MIR129-1 (microRNA 129-1, HGNC:31512) is a microRNA gene on chromosome 7q32.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406917 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31512
Approved symbol	MIR129-1
Name	microRNA 129-1
Location	7q32.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-129-1
Ensembl gene	ENSG00000207705
Ensembl biotype	miRNA
OMIM	621204
Entrez	406917
RNAcentral	URS000075A41E — miRNA, 72 nt, 22 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384972

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384972 — 1 exons

Exon	Start	End
ENSE00001499979	128207872	128207943

Expression profiles

Bgee: expression breadth broad, 16 present calls, max score 71.37.

Top tissues by expression

16 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	71.37	gold quality
islet of Langerhans	UBERON:0000006	70.67	gold quality
skin of leg	UBERON:0001511	70.61	gold quality
nucleus accumbens	UBERON:0001882	69.30	gold quality
ascending aorta	UBERON:0001496	67.36	gold quality
skin of abdomen	UBERON:0001416	65.98	gold quality
omental fat pad	UBERON:0010414	65.43	gold quality
tibial artery	UBERON:0007610	64.67	gold quality
right frontal lobe	UBERON:0002810	62.98	gold quality
cerebellar hemisphere	UBERON:0002245	61.64	gold quality
spleen	UBERON:0002106	60.99	gold quality
left ovary	UBERON:0002119	60.81	gold quality
anterior cingulate cortex	UBERON:0009835	60.52	gold quality
Brodmann (1909) area 9	UBERON:0013540	60.33	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	57.85	gold quality
left testis	UBERON:0004533	43.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.09

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• A direct link between miR-129 and the two putative targets GALNT1 and SOX4 in bladder cancer. (PMID:19487295)
• miR-129-5p is involved in the antitumor activity of HDACi and highlight a miRNA-driven cell death mechanism. (PMID:21946411)
• Low expression of MIR-129 by DNA hypermethylation was associated with gastric cancers. (PMID:21960261)
• The expression of VCP was directly regulated by miR-129-5p and this regulation played an important role in the progression of hepatocellular carcinoma. (PMID:22536440)
• Report miR129-3p orchestrates both the centriole-to-basal body transition and subsequent cilia assembly through microRNA-mediated post-transcriptional regulation. (PMID:22684256)
• our results suggest that gastric juice miR-129-1-3p and miR-129-2-3p are potential biomarkers for the screening gastric cancer (PMID:23307240)
• Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL). (PMID:23463124)
• MiR-129 has a unique potential as a tumor suppressor and a novel candidate for developing miR-129-based therapeutic strategies in colorectal cancer. (PMID:23744359)
• The results show that miR-129-1-3p and miR-129-5p, are down-regulated in gastric cancer cell lines and all of the mature products of miR-129 showed tumor suppressor activities. (PMID:24055727)
• SP1 is a direct target of miR-129-5p in Hela cells (PMID:24358111)
• Expression of miR-129-5p significantly decreases cell growth, induces apoptosis and suppresses migration in medullary thyroid carcinoma cells. (PMID:24631532)
• miR-129-1-3p inhibits gastric cancer cell migration by targeting bradykinin receptor B2. (PMID:25008064)
• High Mirn129 expression is associated with gastric cancer. (PMID:25111461)
• hyper-methylation of miR-129-5p CpG island might play important roles in the development of gastric cancer chemo-resistance by targeting MDR related ABC transporters (PMID:25344911)
• In ovarian cancer cells, miR-129-5p, directly represses TAZ expression, leading to the inactivation of TEA domain transcription, and the downregulation of Hippo downstream genes, connective tissue growth factor and Cyclin A. (PMID:25895125)
• miR-129 suppresses tumor cell growth and invasion by targeting PAK5 in hepatocellular carcinoma. (PMID:26116538)
• Decreased expression of miR-129 is associated with glioblastoma. (PMID:26180082)
• The SNP rs107822G > A in the miR-219-1 gene decreased the risk of Kazakh esophageal squamous cell carcinoma. (PMID:26379361)
• we find that miR-129-5p suppresses breast cancer development and progression (PMID:26460733)
• We demonstrated that restoration of CP110 expression in MDA-MB-231 and MCF-7 cells by miR-129 overexpression rendered the cells sensitive to docetaxel. (PMID:26487539)
• MicroRNA-129-1 acts as tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1 (PMID:26510428)
• miR-129 is significantly downregulated in prostate cancer patients and multivariate analysis confirmed that miR-129 is a novel independent prognostic factor for prostate cancer. (PMID:26823749)
• the findings identify a new function for miR-129 as a potent inducer of autophagy through a novel Notch-1/E2F7/Beclin-1 axis in glioma. (PMID:26824182)
• In tissues of prostate cancer patients, low CP110 and high miR-129-3p expression levels correlated with metastasis (PMID:26918338)
• Decrease in miR-129 expression is associated with Chronic Hepatitis C Related Hepatocellular Carcinoma. (PMID:27268654)
• IL-8 was a direct target of miR-129-5p, and IL-8 was negatively regulated by miR-129-5p and MiR-129-5p regulates migration and invasion of gastric cancer cells by targeting IL-8. (PMID:27468870)
• the potential roles of miR-129 as biomarkers for cancer diagnosis and prognosis, and promising tools for cancer treatment, are reviewed. (PMID:27802440)
• miR-129b suppresses lung cancer cell proliferation, and can be a potential therapeutic target for treatment of lung cancers. (PMID:27813559)
• MALAT1 promoted osteosarcoma cell growth through inhibition of miR-142-3p or miR-129-5p and by targeting HMGB1. (PMID:28346809)
• Data show that suberoylanilide hydroxamic acid (SAHA) induced apoptosis via the down-regulation thioredoxin1 (Trx1), which was regulated by microRNA miR-129-5p. (PMID:28667779)
• the “MALAT1-miR-129-5p” axis might play an important role in the progression of triple-negative breast cancer. (PMID:28915533)
• PCAT-1 repressed inhibitory effect of miR-129-5p and reverse high mobility group box 1 (HMGB1) expression, a target gene of miR-129-5p. (PMID:28931210)
• KSRP, miR-129, and RUNX1 participate in a regulatory axis to control the outcome of myeloid differentiation. (PMID:29127290)
• miR-129-5p level was decreased in fibrotic liver of human, and reduced by rOPN treatment. In contrast, miR-129-5p was induced in HSCs transfected by OPN siRNA. These data suggested that OPN induces Col 1 expression via suppression of miR-129-5p in hepatic stellate cells. (PMID:29196165)
• MiR-129-5p sensitized Her-2-positive breast cancer to trastuzumab by downregulating rpS6. (PMID:29258115)
• KLK7 accelerated the deterioration of PTC in vitro experiments which could be reversed by sh-lnc RNA NEAT1 and miR-129-5p mimics. In vivo experiments, silence of lncRNA NEAT1 restrain tumor growth in weight and volume. (PMID:29319165)
• The reexpression of miR1295p suppressed the cell proliferation, migration and invasion of OS cells. In addition, ROCK1 was confirmed as a direct target of miR1295p. (PMID:29328417)
• Finally, we demonstrate Lamins as the major factors in reliable miR-218 and miR-129 functions for breast cancer progression. Our findings uncover a new miRNA-mediated regulatory network for different Lamins and provide a potential therapeutic target for breast cancer. (PMID:29378184)
• The high expression level of circulating miR-129 in the tissue and blood samples of colorectal cancer patients contributes to aberrant colon cancer cell proliferation and migration mainly by targeting estrogen receptor beta. (PMID:29441863)
• MIRN129 can inhibit the growth of glioblastoma by down-regulating the expression of E2F5. (PMID:29509253)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-129-1	ENSDARG00000082824
danio_rerio	mir129-1b	ENSDARG00000089649
mus_musculus	Mir129-1	ENSMUSG00000065469
rattus_norvegicus	Mir129-1	ENSRNOG00000035598

Paralogs (1): MIR129-2 (ENSG00000199077)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.